ERBB2 and breast carcinoma: A total of 1053 breast cancer tissue samples (including 232 luminal A, 336 luminal B, 134 triple‐negative, and 351 HER‐2‐positive tissue samples) were included, and 49 patients were followed for less than 1 month.